A paradigm shift in the concept of arrhythmogenic cardiomyopathy: expanding the clinical and genetic spectrum, new diagnostic criteria for left ventricular phenotypes

Recent multicenter studies using high-tech cardiac imaging and novel translational technologies have shown that cardiac fibrofatty replacement, characteristic of arrhythmogenic cardiomyopathy (ACM), is observed in both ventricles; left ventricular (LV) involvement may be minimal, on par with the right ventricle (RV), or dominant. In 2019, the Heart Rhythm Society (HRS) proposed a new approach to the assessment of arrhythmic and genetic diseases with the inclusion of new phenotypes — left-dominant ACM and biventricular ACM. In 2020, to improve the diagnosis of left ventricular phenotypes, European experts revised ACM criteria (based on the 2010 ITF criteria), which are called the Padua criteria.

The presented article highlights the clinical and genetic aspects of the new concept and the difficulties in ACM diagnosis, the practical experience of using new diagnostic algorithm. To help practitioners, step-by-step differential diagnosis and risk stratification of right and left ventricular phenotypes are presented using clinical examples (leftdominant ACM with a pathogenic variant in the LMNA gene; right-dominant ACM associated with a desmoplakin gene mutation, with predominant RV and moderate LV involvement; and an isolated RV ACM associated with a mutation in the plakophilin 2 gene).

1. Fontaine G, Chen HS. Arrhythmogenic Right Ventricular Dysplasia Back in Force. Am J Cardiol. 2014; 113(10): 1735-1739. doi:10.1016/j.amjcard.2014.03.001.

2. Marcus FI, Fontaine G, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 cases. Circulation. 1982;65(2):384-398. doi: 10.1161/01.cir.65.2.384.

3. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533-1541. doi: 10.1093/eurheartj/ehq025.

4. Elliott PM, Anastasakis A, Asimaki A, et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail. 2019; 21(8): 955-964. doi:10.1002/ejhf.1534.

5. De Lazzari M, Zorzi A, Cipriani A, et al. Relationship Between Electrocardiographic Findings and Cardiac Magnetic Resonance Phenotypes in Arrhythmogenic Cardiomyopathy. J Am Heart Assoc. 2018;7:e009855-е009866. doi: 0.1161/jaha.118.009855

6. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175-2187. doi: 10.1016/j.jacc.2008.09.019

7. Roberts WC, Ko JM, Kuiper JJ, et al. Some previously neglected examples of arrhythmogenic right ventricular dysplasia/cardiomyopathy and frequency of its various reported manifestations. Am J Cardiol. 2010;106(2):268-274. doi: 10.1016/j.amjcard.2010.03.021.

8. Te Riele AS, Agullo-Pascual E, James CA, et al. Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc Res 2017;113:102–111. doi: 10.1093/cvr/cvw234.

9. Mayosi BM, Fish M, Shaboodien G, et al. Identification of cadherin 2 (CDH2) mutations in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2017;10:e001605-e001617. doi: 10.1161/circgenetics.116.001605.

10. Medeiros-Domingo A, Saguner AM, Magyar I, et al. Arrhythmogenic right ventricular cardiomyopathy: implications of next-generation sequencing in appropriate diagnosis. Europace. 2017;19(6):1063-1069. doi: 10.1093/europace/euw098.

11. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019; 16 (11): e301-e372. doi:10.1016/j.hrthm.2019.05.007

12. Protonotarios A, Elliott PM. Arrhythmogenic cardiomyopathies: diagnosis, risk stratification and management. Heart. 2019;0:1–12. doi:10.1136/heartjnl-2017-311160

13. Caforio ALP, Re F, Avella A, et al. Evidence From Family Studies for Autoimmunity in Arrhythmogenic Right Ventricular Cardiomyopathy: Associations of Circulating Anti-Heart and Anti-Intercalated Disk Autoantibodies With Disease Severity and Family History. Circulation. 2020;141(15):1238-1248. doi: 10.1161/circulationaha.119.043931.

14. Chatterjee D, Fatah M, Akdis D, et al. An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis. European Heart Journal. 2018; 39:3932–3944. doi:10.1093/eurheartj/ehy567

15. Vaikhanskaya TG, Sivitskaya LN, Kurushko TV, et al. Dilated cardiomyopathy: reconceptualization of the problem. Russian Journal of Cardiology. 2019;4:35-47. (In Russ.). doi:10.15829/1560-4071-2019-4-35-47

16. Corrado D, Perazzolo-Marra M, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. International Journal of Cardiology. 2020; doi:10.1016/j.ijcard.2020.06.005.

17. Miles C, Finocchiaro G, Papadakis M, et al. Sudden death and left ventricular involvement in arrhythmogenic cardiomyopathy. Circulation. 2019;139(15):1786-1797. doi: 10.1161/circulationaha.118.037230

18. Casella M, Gasperetti A, Gaetano F, et al. Long-term follow-up analysis of a highly characterized arrhythmogenic cardiomyopathy cohort with classical and non-classical phenotypes– a real-world assessment of a novel prediction model: does the subtype really matter. Europace. 2020;0:1-9. doi:10.1093/europace/euz352

19. Cadrin-Tourigny J, Bosman LP, Nozza A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019;40:1850-1858. doi: 10.1093/eurheartj/ehz195

20. Mattesi G, Zorzi A, Corrado D, et al. Natural History of Arrhythmogenic Cardiomyopathy. J Clin Med. 2020;9(3):878-892. doi:10.3390/jcm9030878.

21. Roudijk RW, Bosman LP, van der Heijden JF, et al. Quantitative Approach to Fragmented QRS in Arrhythmogenic Cardiomyopathy: From Disease towards Asymptomatic Carriers of Pathogenic Variants. J. Clin. Med. 2020;9(2): 545-557. doi:10.3390/jcm9020545

22. Haugaa KH, Basso C, Badano LP, et al. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy - an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18:237-253. doi: 10.1093/ehjci/jew229.

23. Protonotarios A, Elliott PM. Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype? European Cardiology Review 2020;15:11-16. doi: 10.15420/ecr.2019.05